Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Poland

European Research Council grant · Running

ModulatEnds Improving cancer therapy by identification of novel drug leads modulating transcription termination bridging molecular biology and therapeutic applications

Coordinator
Uniwersytet Im. Adama Mickiewicza Wpoznaniu, Poland
Runs
1 January 2026 to 30 June 2027
Status
Running
EU funding
€150k
Total cost
—
Partners
1 organisations in 1 countries
Type
European Research Council grant
Grant agreement
101212992

What the project is doing

In the project's own words, from its summary on CORDIS.

Our value proposition is improving cancer therapy by identification of novel anti-cancer candidate drug leads modulating transcription termination, bridging molecular cancer biology and therapeutic applications. We have developed a methodology to directly measure alterations in transcription termination and successfully subjected it to miniaturization and automatization processes. We are applying for funding to validate a screening platform to identify small molecule inhibitors of transcription termination.

Topics

Who is involved

OrganisationCityCountryRole
Uniwersytet Im. Adama Mickiewicza WpoznaniuPoznanPolandCoordinator

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI